KRAS and melanoma: From 2019 to 2025, ICI applications have grown across both immunogenic cancers (e.g., melanoma) and traditionally resistant types like KRAS-mutant pancreatic cancer and microsatellite-stable colorectal cancer, with synergistic effects observed in non-small cell lung cancer (NSCLC) treated with EGFR inhibitors and ICIs [25,26].